Table 3.
Clinical characteristics of the patients with RA from the first and second replication collections
| First replication | Second replication | |||
|---|---|---|---|---|
| Features | All patients | Infliximab | Adalimumab | Infliximab |
| Patients, number (%) | 404 | 199 (49.3) | 205 (50.7) | 386 |
| Female (%) | 77.2 | 77.9 | 76.6 | 89.1 |
| Age at diagnosis, median (IQR) | 46 (34 to 53) | 42 (33 to 51) | 48 (36 to 56) | 44 (35 to 51) |
| Diagnosis to anti-TNF, median (IQR) | 10 (5 to 17) | 11 (6 to 18) | 9 (4 to 17) | 8 (4 to 15) |
| ACPA, %a | 77.4 | 79.4 | 75.5 | 60.9 |
| Erosive arthritis, %a | 58.2 | 65.0 | 51.1 | 77.6 |
| Smoking, %a | 56.6 | 56.8 | 56.3 | 26.1 |
| Concomitant DMARDs (%)a | 100 | 100 | 100 | 96.4 |
| Baseline HAQ, median (IQR) | 2.0 (1.6 to 2.4) | 2.0 (1.8 to 2.5) | 2.0 (1.5 to 2.3) | 1.9 (1.4 to 2.3) |
| DAS28, (mean ± SD) | ||||
| baseline | 6.5 ± 1.1 | 6.7 ± 1.0 | 6.3 ± 1.1 | 6.1 ± 1.2 |
| six months | 4.1 ± 1.3 | 4.3 ± 1.3 | 3.8 ± 1.2 | 4.1 ± 1.5 |
| six months EULAR response, % | ||||
| responder | 21.3 | 17.1 | 25.4 | 29.2 |
| moderate | 69.6 | 73.4 | 65.9 | 46.9 |
| no-responder | 9.2 | 9.5 | 8.8 | 24.0 |
aData from <85% of patients: in the first replication (310 patients for concomitant DMARDs); in the second replication (196 patients for erosive arthritis; 174 for ACPA; 115 patients for smoking). ACPA, anti-citrullinated peptide antibodies; ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; DMARDs, disease modifying antirheumatic drugs; EULAR, European League against Rheumatism; HAQ, Health Assessment Questionnaire; INX, infliximab; IQR, interquartile range; RA, rheumatoid arthritis; SD, standard deviation.